MAPT and Parkinson disease: CSF and blood NfL levels have been shown to be elevated in PD, more abundantly in PDD and DLB [17–21], and associated with higher levels of CSF αSyn and p-tau biomarkers [22] as well as with measures of cognitive decline [16–18, 20, 23, 24].